Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Controlled Trial: 5-Day Course of Rifampin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2007 by Chosun University Hospital.
Recruitment status was:  Recruiting
Information provided by:
Chosun University Hospital Identifier:
First received: December 5, 2007
Last updated: NA
Last verified: December 2007
History: No changes posted

New antibiotics are required to have not only the antibacterial activity against doxycyline-resistant O. tsutsugamushi but also lower risk for resistance or any cross-resistance to others.

In this prospective, open-label, randomized trial, we enroll patients with mild-to-moderate scrub typhus. We compared the efficacy and safety of a 5-day rifampin therapy with those of a 5-day doxycycline therapy at Chosun University Hospital, or one of its two community-based affiliated hospitals which are all located in southwestern Korea between 2006 and 2009.

Condition Intervention
Scrub Typhus
Drug: doxycycline
Drug: rifampin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Controlled Trial: 5-Day Course of Rifampin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus

Resource links provided by NLM:

Further study details as provided by Chosun University Hospital:

Primary Outcome Measures:
  • The primary end point was the fever clearance time [ Time Frame: 4 years ]

Secondary Outcome Measures:
  • The secondary end point was evaluated according to the following definitions. "Cure ", "Failure", "Relapse" [ Time Frame: 4 years ]

Estimated Enrollment: 476
Study Start Date: September 2006
Estimated Study Completion Date: December 2009
Arms Assigned Interventions
Active Comparator: 1
a 5-day course of daily 200-mg doses of doxycycline
Drug: doxycycline
a 5-day course of 100 mg bid doses of doxycycline
Active Comparator: 2
a 5-day course of daily 600-mg doses of rifampin
Drug: rifampin
a 5-day course of daily 600-mg doses of rifampin


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Inclusion criteria were:

  • Adults aged 18 years or older
  • A fever of higher than 37.5°C
  • The concurrent presence of eschar or a maculopapular skin rash; and the clear presence of more than two symptoms such as headache, malaise, myalgia, coughing, nausea and abdominal discomfort.
  • Patients were hospitalized at Chosun University Hospital in Kwangju, Korea or one of its two community-based affiliated hospitals which are all located in southwestern Korea between 2006 and 2009.

Exclusion Criteria:

The exclusion criteria were:

  • An inability to take oral medications
  • Pregnancy
  • Hypersensitivity to the trial drugs
  • Previous drug therapy with potential antirickettsial activity (e.g., rifampicin, chloramphenicol, macrolides, fluoroquinolones or tetracyclines) within 48 h prior to admission
  • Severe scrub typhus (shock requiring vasopressor therapy for more than one hour
  • A stuporous or comatose level of consciousness
  • Respiratory failure requiring mechanical ventilation or renal failure requiring immediate dialysis) (4, 10).
  • For the differential diagnosis of scrub typhus from other diseases with similar symptoms (e.g., murine typhus, leptospirosis, hemorrhagic fever with renal syndrome and systemic lupus erythematosus), patients underwent diagnostic tests. We thus excluded patients with concurrent infections who had the risk of causing different outcomes.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00568711

Contact: Dong-Min Kim, Prof 82-62-220-3108

Korea, Republic of
Chosun University Hospital Recruiting
Gwang-Joo, Jeollanamdo, Korea, Republic of, 501-717
Contact: Dong-Min Kim, Prof    82-62-220-3108   
Sponsors and Collaborators
Chosun University Hospital
Study Director: Namsoo Cho Director of Chosun University Hospital
  More Information

Responsible Party: Dong-Min Kim, Department of Internal Medicine, Chosun University College of Medicine Identifier: NCT00568711     History of Changes
Other Study ID Numbers: IRB043-31
Study First Received: December 5, 2007
Last Updated: December 5, 2007

Keywords provided by Chosun University Hospital:
Scrub typhus.

Additional relevant MeSH terms:
Typhus, Epidemic Louse-Borne
Scrub Typhus
Rickettsia Infections
Rickettsiaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Anti-Bacterial Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers processed this record on May 25, 2017